Android app on Google Play

VIVUS (VVUS) Qsymia Sales Lag Investor Sentiment in Nov.; Many Expect Better FY13

December 31, 2012 12:13 PM EST Send to a Friend
Get Alerts VVUS Hot Sheet
Price: $4.83 +0.42%

Rating Summary:
    4 Buy, 7 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 22 | Down: 25 | New: 18
Trade VVUS Now!
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) shares are looking a little pressured today following new analyst comments on Qsymia sales.

According to Simos Simeonidis at Cowen, November sales were up 30 percent from October to $452,133. The number is a far cry from investor expectations, Simeonidis noted.

Despite the lagging numbers, Simeonidis sees sales picking up into 2013 with new distribution channels, retail awareness, and reimbursement policies. He noted that VIVUS might need to enter a partnership with "big pharma" of Qsymia is expected to reach "blockbuster" sales.

Final numbers for the quarter won't be made available until VIVUS reports quarterly data due to discrepancies between vendors.

Notably, VIVUS and Express Scripts (Nasdaq: ESRX) entered a deal for Express Scripts to list Qsymia on its national pharmacy formularies, broadening coverage for the obesity pill.

VIVUS is up 0.4 percent Monday, but well off session highs.

For an analyst ratings summary and ratings history on VIVUS, Inc. click here. For more ratings news on VIVUS, Inc. click here.

Shares of VIVUS, Inc. closed at $13.21 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Related Entities

Cowen & Co

Add Your Comment